George Pilcher, MD
Cardiovascular Disease · Jacksonville, FLNPI 1306849583
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $15,032 of the $17,732 with a category attached, or 84.8%. Abiomed accounts for 74.5% of it on its own, with 23 other manufacturers making up the rest. Reporting peaked in 2024 at $4,109 and has fallen 67.8% since, to $1,325 in 2025.
Across 268 payments — averaging $66.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abiomed$13K
- Inari Medical, Inc.$1K
- Abbott$925
- Edwards Lifesciences$686
- Shockwave Medical, Inc$620
- ZOLL Circulation Inc$339
- plus $915 from 18 others
What the payments were for
- Speaking & faculty fees$2,70015%
- Food & beverage$15,03285%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abiomed | 161 | $13,216 |
| Inari Medical, Inc. | 14 | $1,030 |
| Abbott | 14 | $925 |
| Edwards Lifesciences | 7 | $686 |
| Shockwave Medical, Inc | 31 | $620 |
| ZOLL Circulation Inc | 11 | $339 |
| Heartflow, Inc. | 2 | $172 |
| Medtronic(2 entities) | 2 | $145 |
| Johnson & Johnson | 4 | $109 |
| Recor Medical Inc | 1 | $106 |
| Boston Scientific | 4 | $60 |
| Amgen | 3 | $50 |
| Cardiovascular Systems Inc. | 1 | $48 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $47 |
| Braemar Manufacturing, LLC | 1 | $28 |
| Cardiva Medical, Inc. | 1 | $23 |
| Elutia, Inc. | 1 | $20 |
| AstraZeneca | 1 | $18 |
| Astellas Pharma US Inc | 1 | $16 |
| E.r. Squibb & Sons, L.L.C. | 1 | $16 |
| Stryker | 1 | $15 |
| Biosense Webster, Inc. | 1 | $15 |
| Chiesi USA, Inc. | 1 | $14 |
| Novartis | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Impella$8,826
- FLOWTRIEVER CATHETER, S$558
- CT THROMBECTOMY SYSTEM KIT$558
- Mitra Clip system$412
- Edwards SAPIEN 3 Transcatheter Heart Valve$365
- FFRct$144
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$139
- COREVALVE EVOLUT R$134
- NAVITOR$134
- MitraClip System$107
- PARADISE RENAL DENERVATION SYSTEM$106
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$104
How this compares
$17,732 in reported general payments places this provider in the 85th percentile of 1,740 cardiovascular disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 168 | $200,717 |
| EliquisApixaban | 123 | $136,071 |
| Repatha SureclickEvolocumab | 83 | $79,177 |
| JardianceEmpagliflozin | 29 | $32,676 |
| XareltoRivaroxaban | 39 | $31,684 |
| Praluent PenAlirocumab | 15 | $10,942 |
| Atorvastatin Calcium | 456 | $4,823 |
| ClopidogrelClopidogrel Bisulfate | 285 | $3,396 |
| Nebivolol Hcl | 63 | $2,788 |
| Ezetimibe | 143 | $2,763 |
| Rosuvastatin Calcium | 188 | $2,580 |
| Carvedilol | 311 | $2,228 |
| Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide | 143 | $1,951 |
| Amlodipine Besylate | 218 | $1,878 |
| Metoprolol Succinate | 105 | $1,153 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $13 | $200,717168 claims |
| Johnson & JohnsonXarelto | $109 | $31,68439 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,740 cardiovascular disease providers in Florida.
Other cardiovascular disease in Jacksonville
- Alan MillerJacksonville$547K
- Samer GarasJacksonville$258K
- Jose Nativi-NicolauJacksonville$125K
- Kevin MakatiLutz$1.6M
- Hiram BezerraTampa$698K
- William OneillNaples$637K
- Theodore FeldmanMiami$637K
- John Gerald CantoLakeland$588K
- Seth BaumBoca Raton$517K
- Elliott EliasMiami$497K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.